New hope for breast cancer patients whose tumors resisted standard therapy
NCT ID NCT06702618
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 study tests a new drug (TQB3616) combined with hormone therapy for people with a common type of breast cancer (HR-positive, HER2-negative) that has returned or spread and no longer responds to a standard class of drugs called CDK4/6 inhibitors. The trial enrolls 33 adults aged 18-75 who have already tried a CDK4/6 inhibitor. The main goal is to see if the tumor shrinks or disappears, and researchers also track how long the benefit lasts.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cancer Hospital of Shandong First Medical University(Shandong Cancer Institute, Shandong Cancer Hospital)
Jinan, Shandong, 250117, China
-
Hai'an People's Hospital
Nantong, Jiangsu, 226600, China
-
Harbin Medical University Cancer Hostipal
Harbin, Heilongjiang, 150000, China
-
Hunan Cancer Hospital
Changsha, Hunan, 410010, China
-
Jiangmen Central Hospital
Jiangmen, Guangdong, 529000, China
-
Jiangsu Provincial People's Hospital
Nanjing, Jiangsu, 210003, China
-
Liaoning Cancer Hospital
Shenyang, Liaoning, 110000, China
-
Luohe Central Hospital
Luohe, Henan, 462000, China
-
The Affiliated Hospital of Southwest Medical University
Luzhou, Sichuan, 646000, China
-
The First Affiliated Hospital of Xi'an Jiao Tong University
Xi’an, Shanxi, 710061, China
-
The First Affilliated Hospital of Bengbu Medical University
Bengbu, Anhui, 233000, China
-
Tianjin Medical University Cancer Institute & Hospital
Tianjin, Tianjin Municipality, 300202, China
-
Xingtai People's Hospital
Xingtai, Hebei, 54000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Chest-Injected drug drain Cancer's fluid trap?
- A dab of gel on the breathing tube might spare surgery patients a sore throat — a trial puts it to the test.
- Can a deeper nerve block ease pain after breast surgery?
- Does breast cancer radiation harm a key immune gland? a study investigates
- A web program may ease the emotional toll of chemotherapy hair loss
- Can 3D breast imaging spot more dangerous cancers than standard mammograms?